A META-ANALYSIS of COGNITIVE BEHAVIOR THERAPY and MEDICATION for CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS of TREATMENT EFFICACY, RESPONSE, and REMISSION

Depression and Anxiety

Volumn 32, Issue 8, 2015, Pages 580-593

  McGuire, Joseph F ^a,b,c   Piacentini, John ^c   Lewin, Adam B ^a,b   Brennan, Erin A ^b   Murphy, Tanya K ^b   Storch, Eric A ^a,b,d,e,f  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Rogers Behavioral Health Tampa Bay   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

clomipramine; cognitive behavior therapy; diagnostic remission; obsessive compulsive disorder; selective serotonin reuptake inhibitors; treatment outcome; treatment response

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY ASSESSMENT; ANXIETY DISORDER; ANXIETY DISORDER INTERVIEW SCHEDULE CHILD AND PARENT REPORT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDREN YALE BROWN OBSESSIVE COMPULSIVE SCALE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; GILLES DE LA TOURETTE SYNDROME; HUMAN; META ANALYSIS; NATIONAL INSTITUTE OF MENTAL HEALTH GLOBAL OBSESSIVE COMPULSIVE DISORDER SCALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT RESPONSE; ADOLESCENT; MULTIMODALITY CANCER THERAPY; OBSESSIVE-COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; OUTCOME ASSESSMENT (HEALTH CARE); REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS;

EID: 84937966015     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22389     Document Type: Article

References (69)

1. Zohar AH., The epidemiology of obsessive-compulsive disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am 1999; 8 (3): 445-460.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Association; 2013.
3. Ruscio AM, Stein DJ, Chiu WT, Kessler RC,. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatr 2010; 15 (1): 53-63.
4. Nestadt G, Samuels J, Riddle M, et al., A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57 (4): 358-363.
5. Geller DA, Biederman J, Faraone S, et al., Developmental aspects of obsessive compulsive disorder: findings in children, adolescents, and adults. J Nerv Ment Dis 2001; 189 (7): 471-477.
6. Farrell L, Barrett P, Piacentini J,. Obsessive-compulsive disorder across the developmental trajectory: clinical correlates in children, adolescents and adults. Behav Change 2006; 23 (2): 103-120.
7. Piacentini J, Peris TS, Bergman RL, et al., Functional impairment in childhood OCD: development and psychometrics properties of the Child Obsessive-Compulsive Impact Scale-Revised (COIS-R). J Clin Child Adolesc Psychol 2007; 36 (4): 645-653.
8. Lebowitz ER, Panza KE, Su J, Bloch MH,. Family accommodation in obsessive-compulsive disorder. Expert Rev Neurother 2012; 12 (2): 229-238.
9. Lack CW, Storch EA, Keeley ML, et al., Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent-child agreement, and clinical correlates. Soc Psychiatry Psychiatr Epidemiol 2009; 44 (11): 935-942.
10. Stewart SE, Geller DA, Jenike M, et al., Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatr Scand 2004; 110 (1): 4-13.
11. Geller DA, March J,. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2012; 51 (1): 98-113.
12. Lewin AB, Wu MS, McGuire JF, Storch EA,. Cognitive behavioral therapy for obsessive-compulsive and related disorders. Psychiatr Clin N Am 2014; 37 (3): 415-445.
13. Freeman J, Garcia A, Frank H, et al., Evidence base update for psychosocial treatments for pediatric obsessive-compulsive disorder. J Clin Child Adolesc Psychol 2014; 43 (1): 7-26.
14. Williams TI, Salkovskis PM, Forrester L, et al., A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. Eur Child Adolesc Psychiatry 2010; 19 (5): 449-456.
15. Barrett P, Healy-Farrell L, March JS,. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43 (1): 46-62.
16. Bolton D, Perrin S,. Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. J Behav Ther Exp Psychiatry 2008; 39 (1): 11-22.
17. Bolton D, Williams T, Perrin S, et al., Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. J Child Psychol Psychiatry 2011; 52 (12): 1269-1278.
18. Storch EA, Caporino NE, Morgan JR, et al., Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res 2011; 189 (3): 407-412.
19. POTS. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292 (16): 1969-1976.
20. Lewin AB, Park JM, Jones AM, et al., Family-based exposure and response prevention therapy for preschool-aged children with obsessive-compulsive disorder: a pilot randomized controlled trial Behav Res Ther 2014; 56: 30-38.
21. Freeman JB, Garcia AM, Coyne L, et al., Early childhood OCD: preliminary findings from a family-based cognitive-behavioral approach. J Am Acad Child Adolesc Psychiatry 2008; 47 (5): 593-602.
22. Piacentini J, Bergman RL, Chang S, et al., Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2011; 50 (11): 1149-1161.
23. Freeman J, Sapyta J, Garcia A, et al., Family-based treatment of early childhood obsessive-compulsive disorder: the Pediatric Obsessive-Compulsive Disorder Treatment Study for Young Children (POTS Jr)-a randomized clinical trial. JAMA Psychiatry 2014; 71 (6): 689-698.
24. O'Leary EMM, Barrett P, Fjermestad KW,. Cognitive-behavioral family treatment for childhood obsessive-compulsive disorder: a 7-year follow-up study. J Anxiety Disord 2009; 23 (7): 973-978.
25. Lewin AB, McGuire JF, Murphy TK, Storch EA,. Editorial perspective: the importance of considering parent's preferences when planning treatment for their children-the case of childhood obsessive-compulsive disorder. J Child Psychol Psychiatry 2014; 55 (12): 1314-1316.
26. de Haan E, Hoogduin KAL, Buitelaar JK, Keijsers GPJ,. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998; 37 (10): 1022-1029.
27. DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell DP,. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31 (1): 45-49.
28. Flament MF, Rapoport JL, Berg CJ, et al.,. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985; 42 (10): 977-983.
29. March JS, Biederman J, Wolkow R, et al., Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280 (20): 1752-1756.
30. Liebowitz MR, Turner SM, Piacentini J, et al., Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (12): 1431-1438.
31. Geller DA, Hoog SL, Heiligenstein JH, et al., Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (7): 773-779.
32. Riddle MA, Scahill L, King RA, Hardin MT,. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31 (6): 1062-1069.
33. Geller DA, Wagner KD, Emslie G, et al., Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43 (11): 1387-1396.
34. Riddle MA, Reeve EA, Yaryura-Tobias JA, et al., Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 222-229.
35. Geller DA, Biederman J, Stewart SE, et al., Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatr 2003; 160 (11): 1919-1928.
36. Wagner KD, Cook EH, Chung H, Messig M,. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003; 13 (2,Suppl): S53-S60.
37. Semerci ZB, Unal F,. An open trial and discontinuation study of fluoxetine in children and adolescents with obsessive-compulsive disorder. Turk J Pediatr 2001; 43 (4): 323-328.
38. Geller DA, Biederman J, Stewart SE, et al., Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 2003; 13 (Suppl 1): S19-S29.
39. Murphy TK, Segarra A, Storch EA, Goodman WK,. SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 2008; 20 (2): 203-208.
40. Bridge JA, Iyengar S, Salary CB, et al., Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297 (15): 1683-1696.
41. Murad MH, Montori VM,. Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA 2013; 309 (21): 2217-2218.
42. Ginsburg GS, Kingery JN, Drake KL, Grados MA,. Predictors of treatment response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2008; 47 (8): 868-878.
43. Garcia AM, Sapyta JJ, Moore PS, et al., Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am Acad Child Adolesc Psychiatry 2010; 49 (10): 1024-1033; quiz 1086.
44. March JS, Franklin ME, Leonard H, et al., Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007; 61 (3): 344-347.
45. Storch EA, Merlo LJ, Larson MJ, et al., Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2008; 47 (5): 583-592.
46. Bloch MH., Meta-analysis and moderator analysis: can the field develop further? J Am Acad Child Adolesc Psychiatry 2014; 53 (2): 135-137.
47. Freeman JB, Choate-Summers ML, Moore PS, et al., Cognitive behavioral treatment for young children with obsessive-compulsive disorder. Biol Psychiatry 2007; 61 (3): 337-343.
48. O'Kearney R., Benefits of cognitive-behavioural therapy for children and youth with obsessive-compulsive disorder: re-examination of the evidence. Aust N Z J Psychiatry 2007; 41 (3): 199-212.
49. O'Kearney RT, Anstey KJ, von Sanden C,. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev 2010;(4): CD004856.
50. Abramowitz J, Whiteside SP, Deacon B,. The effectiveness of treatment for pediatric obsessive-compulsive disorder: a meta-analysis. Behav Ther 2005; 36: 55-63.
51. Watson HJ, Rees CS,. Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry 2008; 49 (5): 489-498.
52. Sanchez-Meca J, Rosa-Alcazar AI, Iniesta-Sepulveda M, Rosa-Alcazar A,. Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: a meta-analysis. J Anxiety Disord 2013; 28 (1): 31-44.
53. Storch EA, Park JM, Lewin AB, et al., The Leyton Obsessional Inventory-Child Version survey form does not demonstrate adequate psychometric properties in American youth with pediatric obsessive-compulsive disorder. J Anxiety Disord 2011; 25 (4): 574-578.
54. Frank E, Prien RF, Jarrett RB, et al., Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48 (9): 851-855.
55. Storch EA, Lewin AB, de Nadai AS, Murphy TK,. Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. J Am Acad Child Adolesc Psychiatry 2010; 49 (7): 708-717.
56. Franklin ME, Sapyta J, Freeman JB, et al., Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA 2011; 306 (11): 1224-1232.
57. Storch EA, Bussing R, Small BJ, et al., Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther 2013; 51 (12): 823-829.
58. Romanelli RJ, Wu FM, Gamba R, et al., Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Depress Anxiety 2014; 31 (8): 641-652.
59. Scahill L, Riddle MA, McSwiggin-Hardin M, et al., Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997; 36 (6): 844-852.
60. Insel TR, Murphy DL, Cohen RM, et al., Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40 (6): 605-612.
61. Guy W,. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute for Mental Health; 1976: 218-222.
62. Silverman WK, Albano AM,. The Anxiety Disorders Interview Schedule for DSM-IV-Child and Parent Versions. San Antonio, TX: Graywinds Publications; 1996.
63. Moncrieff J, Churchill R, Drummond DC, McGuire H,. Development of a quality assessment instrument for trials of treatments for depression and neurosis. Int J Methods Psychiatr Res 2001; 10 (3): 126-133.
64. McGuire JF, Piacentini J, Brennan EA, et al., A meta-analysis of behavior therapy for Tourette syndrome. J Psychiatr Res 2014; 50: 106-112.
65. McGuire JF, Ung D, Selless RR, et al., Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. J Psychiatr Res 2014; 58: 76-83.
66. Borenstein M, Hedges L, Higgins J, Rothstein H,. Comprehensive Meta-analysis. Version 2. Englewood, NJ: Biostat; 2005.
67. McGough JJ, Faraone SV,. Estimating the size of treatment effects: moving beyond P values. Psychiatry 2009; 6 (10): 21-29.
68. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR,. Introduction to Meta-Analysis. West Sussex, UK: Wiley; 2009.
69. Conelea CA, Walther MR, Freeman JB, et al., Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II. J Am Acad Child Adolesc Psychiatry 2014; 53 (12): 1308-1316.